Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants
- PMID: 23992673
- PMCID: PMC4120744
- DOI: 10.1016/j.jpeds.2013.07.027
Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants
Abstract
Objective: To evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18-22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants.
Study design: Evaluation of infants at 18-22 months corrected age included anthropomorphic measurements, a standard neurological examination, and the Bayley Scales of Infant Development-II, including the Mental Developmental Index and the Psychomotor Developmental Index. NDI was defined as moderate or severe cerebral palsy, Mental Developmental Index or Psychomotor Developmental Index <70, blindness, or hearing impairment.
Results: Death or NDI at 18-22 months corrected age was similar in the dexamethasone and placebo groups (65% vs 66%, P = .99 among those with known outcome). The proportion of survivors with NDI was also similar, as were mean values for weight, length, and head circumference and the proportion of infants with poor growth (50% vs 41%, P = .42 for weight less than 10th percentile); 49% of infants in the placebo group received treatment with corticosteroid compared with 32% in the dexamethasone group (P = .02).
Conclusion: The risk of death or NDI and rate of poor growth were high but similar in the dexamethasone and placebo groups. The lack of a discernible effect of early dexamethasone on neurodevelopmental outcome may be due to frequent clinical corticosteroid use in the placebo group.
Keywords: CLD; Chronic lung disease; ELBW; Extremely low birth weight; GI; Gastrointestinal; MDI; Mental Developmental Index; NDI; Neurodevelopmental impairment; PDI; Psychomotor Developmental Index.
Copyright © 2014 Mosby, Inc. All rights reserved.
Comment in
-
Stopping the swinging pendulum of postnatal corticosteroid use.J Pediatr. 2014 Jan;164(1):9-11. doi: 10.1016/j.jpeds.2013.10.020. J Pediatr. 2014. PMID: 24359899 Free PMC article. No abstract available.
References
-
- Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<8 days) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2010;(1):CD001146. - PubMed
-
- Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009;(1):CD001145. - PubMed
-
- American Academy of Pediatrics Committee on Fetus and Newborn. Policy statement -Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 2010;126(2):800–8. - PubMed
-
- Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely low birth weight infants. N Engl J Med. 2001;344:95–101. - PubMed
-
- Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics. 2000;105:1215–1226. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 HD27851/HD/NICHD NIH HHS/United States
- U10 HD021385/HD/NICHD NIH HHS/United States
- UL1 RR25008/RR/NCRR NIH HHS/United States
- UL1 RR025744/RR/NCRR NIH HHS/United States
- M01 RR2635/RR/NCRR NIH HHS/United States
- M01 RR16587/RR/NCRR NIH HHS/United States
- U10 HD21397/HD/NICHD NIH HHS/United States
- M01 RR8084/RR/NCRR NIH HHS/United States
- UL1 RR025008/RR/NCRR NIH HHS/United States
- U10 HD21385/HD/NICHD NIH HHS/United States
- U10 HD27881/HD/NICHD NIH HHS/United States
- U10 HD40689/HD/NICHD NIH HHS/United States
- U10 HD021373/HD/NICHD NIH HHS/United States
- U10 HD21364/HD/NICHD NIH HHS/United States
- U10 HD34216/HD/NICHD NIH HHS/United States
- UL1 RR25744/RR/NCRR NIH HHS/United States
- U10 HD021364/HD/NICHD NIH HHS/United States
- U10 HD027880/HD/NICHD NIH HHS/United States
- U10 HD36790/HD/NICHD NIH HHS/United States
- M01 RR002172/RR/NCRR NIH HHS/United States
- UG1 HD087229/HD/NICHD NIH HHS/United States
- M01 RR2172/RR/NCRR NIH HHS/United States
- U10 HD27880/HD/NICHD NIH HHS/United States
- U10 HD27904/HD/NICHD NIH HHS/United States
- UL1 TR000093/TR/NCATS NIH HHS/United States
- U10 HD27871/HD/NICHD NIH HHS/United States
- M01 RR016587/RR/NCRR NIH HHS/United States
- M01 RR1032/RR/NCRR NIH HHS/United States
- M01 RR002635/RR/NCRR NIH HHS/United States
- U10 HD040689/HD/NICHD NIH HHS/United States
- M01 RR001032/RR/NCRR NIH HHS/United States
- U10 HD027853/HD/NICHD NIH HHS/United States
- U10 HD027904/HD/NICHD NIH HHS/United States
- U10 HD021397/HD/NICHD NIH HHS/United States
- U10 HD034167/HD/NICHD NIH HHS/United States
- U10 HD27853/HD/NICHD NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- U10 HD027871/HD/NICHD NIH HHS/United States
- UL1 TR001085/TR/NCATS NIH HHS/United States
- U10 HD027851/HD/NICHD NIH HHS/United States
- U10 HD034216/HD/NICHD NIH HHS/United States
- U10 HD036790/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
